Abcam PLC (LSE:ABC) - Share price


Stock Report

Abcam PLC ABC

Last Price
GBX1,145.00

Day Change
23.00|2.05%

As of 26/05/2022
17:56:09 BST | GBX
Minimum 15 Minutes Delay.

Last Close1,122.00p
Day Range1,116.00 - 1,153.00
Mkt Cap2.62Bil
52-Wk Range1,013.57 - 1,780.00
Yield %0.23
ISINGB00B6774699
Volume132,783
P/E169.49
P/S0.09
P/CF0.38

Share Price

Total Returns 26/05/2022

 Chg (%)  
More ...
Abcam PLC-10.83 
FTSE 100 TR GBP2.81
 
Financials
201820192020
More ...
Income Statement
Turnover233.20259.90260.00
Operating Profit75.4055.3036.10
Net Profit62.2044.4012.50
Reported EPS30.2021.506.00
Balance Sheet
Current Assets159.90171.80278.80
Non Current Assets254.90272.80530.50
Total Assets414.80444.60809.30
Current Liabilities49.0045.30159.60
Total Liabilities63.1061.50308.40
Total Equity351.70383.10500.90
Cash Flow
Operating Cash Flow72.9082.8065.40
Net Change in Cash5.00-4.4099.50

Regulatory News

DateAuthor Headline
24/04/2014Holly Cook 3 VCTs for Enjoying Tax-Free Returns
ASK THE EXPERT: Harry Driscoll of Chelsea Financial Services explains why VCTs can be so attractive, and offers some ideas for investors interested in this area
20/02/2014Emma Wall Top Managers' Favourite Small-Cap Stocks
These five UK small-cap stocks have all caught the attention of our highest-rated fund managers
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
16/03/2022PurchaseMr. Michael Shaun Baldock17.005,910100,450.00
03/02/2022Transfer inMr. Michael Shaun Baldock0.003,3010.00
12/11/2021Transfer inMr. Alan Thomas Hirzel0.00116,3010.00
12/11/2021SaleMr. Alan Thomas Hirzel1,689.0054,799925,555.00

Company Profile

Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.

Sector

Biotechnology

Index

FTSE AIM UK 50 , FTSE AIM 100 , FTSE AIM All-Share

Next Event 13/09/2022

Half-Yearly Results
Ratios
Comp
More ...
PER (E)189.39
Div Yld (E)0.00
PEG (E)0.00
ROCE1.71
Op Mrgn0.14
EPS Grwth-0.26
Dividends
PreviousLatest
More ...
Record Date08/11/1920/03/20
Ex-Div07/11/1919/03/20
Paid29/11/1917/04/20
Amnt8.583.55
Directors
More ...
Independent DirectorMr. Giles Francis Bertram Kerr
Chairman of the BoardMr. Peter Vance Allen
Chief Executive Officer and DirectorMr. Alan Thomas Hirzel
Independent DirectorMs. Mara Glickman Aspinall
Chief Financial Officer and DirectorMr. Michael Shaun Baldock
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2022 Morningstar. All rights reserved.